FTY720 reduces inflammation and promotes functional recovery after spinal cord injury. 2009

Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
Department of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA.

A robust and complex inflammatory cascade is known to be a prominent component of secondary injury following spinal cord injury (SCI). Specifically, the concept of trauma-induced autoimmunity has linked the lymphocyte population with neural tissue injury and neurologic deficit. FTY720, a sphingosine receptor modulator that sequesters lymphocytes in secondary lymphoid organs, has been shown to be effective in the treatment of a variety of experimental autoimmune disorders. Accordingly, by reducing lymphocyte infiltration into the spinal cord following SCI, this novel immunomodulator may enhance tissue preservation and functional recovery. In the present study, a moderate to severe contusion SCI was simulated in adult Long-Evans hooded rats. Using flow cytometry we showed that daily FTY720 treatment dramatically reduced T-cell infiltration into the SCI lesion site at 4 and 7 days post-injury, while other inflammatory cell populations were relatively unaltered. To assess functional recovery, three groups of injured animals (treated, vehicle, and injury only) were evaluated weekly for hindlimb recovery. Animals in the treated group consistently exhibited higher functional scores than animals in the control groups after 2 weeks post-injury. This finding was associated with a greater degree of white matter sparing at the lesion epicenter when cords were later sectioned and stained. Furthermore, treated animals were found to exhibit improved bladder function and a reduced incidence of hemorrhagic cystitis compared to control counterparts. Collectively these results demonstrate the neuroprotective potential of FTY720 treatment after experimental SCI.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D009187 Myelitis Inflammation of the spinal cord. Relatively common etiologies include infections; AUTOIMMUNE DISEASES; SPINAL CORD; and ischemia (see also SPINAL CORD VASCULAR DISEASES). Clinical features generally include weakness, sensory loss, localized pain, incontinence, and other signs of autonomic dysfunction. Myelopathy, Inflammatory,Spinal Cord Inflammation,Subacute Necrotizing Myelitis,Infectious Myelitis,Inflammation, Spinal Cord,Inflammations, Spinal Cord,Inflammatory Myelopathies,Inflammatory Myelopathy,Myelitides,Myelitides, Subacute Necrotizing,Myelitis, Infectious,Myelitis, Subacute Necrotizing,Myelopathies, Inflammatory,Necrotizing Myelitides, Subacute,Necrotizing Myelitis, Subacute,Spinal Cord Inflammations,Subacute Necrotizing Myelitides
D009413 Nerve Fibers, Myelinated A class of nerve fibers as defined by their structure, specifically the nerve sheath arrangement. The AXONS of the myelinated nerve fibers are completely encased in a MYELIN SHEATH. They are fibers of relatively large and varied diameters. Their NEURAL CONDUCTION rates are faster than those of the unmyelinated nerve fibers (NERVE FIBERS, UNMYELINATED). Myelinated nerve fibers are present in somatic and autonomic nerves. A Fibers,B Fibers,Fiber, Myelinated Nerve,Fibers, Myelinated Nerve,Myelinated Nerve Fiber,Myelinated Nerve Fibers,Nerve Fiber, Myelinated
D009416 Nerve Regeneration Renewal or physiological repair of damaged nerve tissue. Nerve Tissue Regeneration,Nervous Tissue Regeneration,Neural Tissue Regeneration,Nerve Tissue Regenerations,Nervous Tissue Regenerations,Neural Tissue Regenerations,Regeneration, Nerve,Regeneration, Nerve Tissue,Regeneration, Nervous Tissue,Regeneration, Neural Tissue,Tissue Regeneration, Nerve,Tissue Regeneration, Nervous,Tissue Regeneration, Neural
D010243 Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45) Palsy,Plegia,Todd Paralysis,Todd's Paralysis,Palsies,Paralyses,Paralysis, Todd,Paralysis, Todd's,Plegias,Todds Paralysis
D011409 Propylene Glycols Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations. Propanediols,Glycols, Propylene
D001750 Urinary Bladder, Neurogenic Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES. Bladder Disorder, Neurogenic,Neurogenic Bladder,Bladder Neurogenesis,Bladder, Neurogenic,Neurogenic Bladder Disorder,Neurogenic Bladder, Atonic,Neurogenic Bladder, Spastic,Neurogenic Bladder, Uninhibited,Neurogenic Dysfunction of the Urinary Bladder,Neurogenic Urinary Bladder Disorder,Neurogenic Urinary Bladder, Atonic,Neurogenic Urinary Bladder, Spastic,Neurogenic Urinary Bladder, Uninhibited,Neuropathic Bladder,Urinary Bladder Disorder, Neurogenic,Urinary Bladder Neurogenesis,Urinary Bladder Neurogenic Dysfunction,Atonic Neurogenic Bladder,Neurogenesis, Bladder,Neurogenesis, Urinary Bladder,Neurogenic Bladder Disorders,Neurogenic Urinary Bladder,Spastic Neurogenic Bladder,Uninhibited Neurogenic Bladder
D002634 Chemotaxis, Leukocyte The movement of leukocytes in response to a chemical concentration gradient or to products formed in an immunologic reaction. Leukotaxis,Leukocyte Chemotaxis
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal

Related Publications

Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
December 2009, The Tohoku journal of experimental medicine,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
October 2008, Molecular and cellular neurosciences,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
August 2013, Neuroscience bulletin,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
April 2012, The American journal of pathology,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
January 2016, Neural plasticity,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
April 2002, Nature,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
August 2021, Molecular therapy : the journal of the American Society of Gene Therapy,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
June 2019, Journal of molecular neuroscience : MN,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
April 2021, Neuroreport,
Kangmin D Lee, and Woon N Chow, and Carmen Sato-Bigbee, and Martin R Graf, and Robert S Graham, and Raymond J Colello, and Harold F Young, and Bruce E Mathern
October 2023, CNS neuroscience & therapeutics,
Copied contents to your clipboard!